DiagnaMed Strengthens Leadership Team and Confirms Completion of Extensive Hydrogen Soil Sampling Program in Ontario's Temiscamingue Graben

Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or "DMED" or the "Company") is pleased to announce the appointment of **André Turmel as Executive Chairman** and **Pam Sangster as Strategic Advisor**, further enhancing the Company's leadership bench as it prepares for the upcoming release of exploration results from its flagship program in Ontario's Témiscamingue Graben.

The program, carried out in collaboration with **Quebec Innovative Materials Corp. (QIMC)** and **Institut National de la Recherche Scientifique (INRS)**, involved the collection of more than **1,000 soil-gas samples** across the property. The comprehensive dataset is now being analyzed, with results to be rolled out in the coming weeks as part of DiagnaMed's next phase of growth.

"These appointments come at a pivotal moment for DMED," said **John Karagiannidis, CEO of DMED**. "André's proven leadership in renewables and governance, combined with Pam's technical expertise and deep community ties, will provide invaluable guidance as we release the results of our Témiscamingue Graben program. This work represents a major step forward in positioning DiagnaMed, alongside partner QIMC, as leaders in the emerging Canadian natural hydrogen sector."

Corporate Updates

André Turmel brings over **25 years of experience in the renewable energy sector** to his new role. He has been a **senior partner at Fasken LLP**, one of Canada's largest law firms, specializing in energy, natural resources, and climate change law, and has been recognized by *Best Lawyers in Canada* in Energy Law since 2006. At Fasken, Mr. Turmel co-led the firm's **Global Energy Group**. He has served as **Chair of the Canadian Bar Association – National Environment, Energy and Natural Resources Law Section** and as **Chair of the Foundation of the Partners of the Biosphere of Montreal** (Water, Ecosystem and Climate Change Museum of Environment Canada). As Executive Chairman of DMED, he will strengthen corporate strategy, partnerships, and stakeholder engagement.

Pam Sangster brings over **30 years of experience in the mineral resource sector**. A **Professional Geoscientist** and former **Regional Resident Geologist with the Ontario Geological Survey**, she has held senior roles including **Provincial Industrial Mineral Specialist**, **Regional Land Use Planning Geologist**, **Manager of the Provincial Mines and Minerals Information Centre**, and **District Geologist in Timmins**. She offers deep expertise in mineral exploration, land use planning, and industrial minerals, with strong ties to industry, government, and Indigenous communities. As Strategic Advisor, Ms. Sangster will help guide DMED's exploration programs and stakeholder relations.

About DiagnaMed Holdings Corp.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a Canadian technology company that delivers innovative solutions for the clean tech and life sciences industries. Visit DiagnaMed.com. For more information, please contact:

John Karagiannidis, President and CEO

DiagnaMed Holdings Corp.

Tel: 514-726-7058
Email: info@diagnamed.com
Website: www.diagnamed.com

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "projected", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the Three and Six Months Ended March 31, 2025 ("MD&A"), dated May 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

DiagnaMed
CSE:DMED OTC:DGNMF

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268437